Systolic time intervals (STI) and serum digoxin concentrations (SDC) were measured in eight patients with compensated atherosclerotic and/or hypertensive heart disease who received oral digoxin 0.25 mg/day or 0.5 mg/day for alternate two-week periods without a loading dose. Control data were obtained both before and after the four weeks of treatment. After 13 days treatment with digoxin, 0.5 mg/day, there was a significant decrease in total electromechanical systole corrected for heart rate (QS2i), pre-ejection period (PEP), pre-ejection period corrected for heart rate (PEP,) Methods Eight patients, all in normal sinus rhythm, with compensated atherosclerotic and/or hypertensive heart disease were studied. Four patients were male and four patients were female. Ages ranged from 35 years to 68 years. Five patients were receiving maintenance doses of digoxin, orally, at the time of selection for the study. Digoxin was discontinued at least two weeks prior to the first control observation. In all patients, SDC at the time of the first control observation was less than 0.4 ng/ml. Diuretics, antihypertensive agents, and sedatives were continued in unchanged doses. Patients taking diuretics received supplemental oral potassium chloride. The purpose of the study was fully explained to each patient and written informed consent was obtained.
correlation between serum glycoside levels and incidence of digitalis toxicity.1 Much less information is available concerning possible relationships between serum glycoside levels and therapeutic efficacy. Ventricular rate has been studied in patients with atrial fibrillation,2 3 and patients have been graded according to "clinical response. "3 4 There have been only limited attempts to relate serum digoxin concentrations (SDC) to an objective index of contractility in patients receiving oral maintenance regimens of digoxin.5
In the present study, patients with compensated heart disease (New York Heart Association Class I or II) received digoxin, 0.25 mg or 0.5 mg/day, for alternate two-week periods without a loading dose. For each dosage regimen, SDC and systolic time intervals (STI) were measured at intervals of 24 hours after the thirteenth dose, and 1/2, 1, 2, and 4 hours after the fourteenth dose. These values were then compared to control data obtained before and after the four weeks of treatment. This information has prov/ded an estimate of the inotropic effectiveness of usual maintenance regimens of digoxin in outpatients and has permitted the comparison of STI and SDC.
Methods
Eight patients, all in normal sinus rhythm, with compensated atherosclerotic and/or hypertensive heart disease were studied. Four patients were male and four patients were female. Ages ranged from 35 years to 68 years. Five patients were receiving maintenance doses of digoxin, orally, at the time of selection for the study. Digoxin was discontinued at least two weeks prior to the first control observation. In all patients, SDC at the time of the first control observation was less than 0.4 ng/ml. Diuretics, antihypertensive agents, and sedatives were continued in unchanged doses. Patients taking diuretics received supplemental oral potassium chloride. The purpose of the study was fully explained to each patient and written informed consent was obtained.
The initial evaluation of each patient included determinations of blood urea nitrogen, serum creatinine, sodium, potassium, chloride, carbon dioxide combining power, calcium, carotene, and thyroxine. The results of these studies were all within the normal range. Chest X-rays and 12-lead electrocardiograms were compatible with the clinical diagnoses.
Two sets of control observations (Cl and C2) were obtained two weeks before starting digoxin. Four of the patients then received digoxin 0.25 mg/day for two weeks Circulation, Volume 50, July 19, 74 and 0.5 mg/day for the next two weeks. The other four patients received 0.5 mg/day for the first two weeks and 0.25 mg/day for the second two weeks. Treatment values were recorded on the last day of each two-week treatment period. A third set of control observations (C3) was obtained two weeks after digoxin was discontinued.
Baseline STI recordings were made between 8:30 and 9:30 a.m. in the fasting state after the patient had been resting quietly in bed for at least 15 minutes. Patients who smoked had been instructed to abstain on the day of study. Additional STI were obtained at l/2, 1, 2, and 4 hours after baseline recordings. A light meal without coffee, tea or cola drinks was permitted after the two-hour recording.
On days Cl, C2, and C3, blood for SDC was obtained at the times of the baseline STI recordings. The fourteenth daily dose of digoxin (either 0.25 or 0.5 mg) was given in the laboratory 24 hours following the previous day's dose and immediately after the baseline STI recording and SDC. On the days of study, blood for SDC was also obtained at the time of each subsequent STI recording through an indwelling intravenous catheter. All patients received the same brand of oral digoxin (Lanoxin, Burroughs Wellcome Co.).
Serum digoxin concentration was determined by the tritiated digoxin radioimmunoassay method' utilizing a commercially available kit (Schwarz Mann Co.). All determinations were performed in duplicate and the two results were averaged. The mean difference between the duplicate determinations was 0.04 ng/ml with a standard error of the difference of 0.016 ng/ml. In this study, assay results of less than 0.4 ng/ml were considered as 0.4 ng/ml.
Electrocardiograms, phonocardiograms, and carotid arterial pulse tracings were recorded on a six-channel photographic recorder at a speed of 100 mm/sec. The electrocardiographic leads selected were the bipolar chest lead CM5, and the Frank orthogonal leads X, Y, and Z. The Figure 2 Changes in PEP' after 0.25 mg or 0.5 mg digoxin following two weeks of maintenance therapy. Statistical analysis is the same as figure 1. values obtained at the 0.5 mg dose were less than those obtained at the 0.25 mg dose except for the fourhour recording of QS2i.
Serum Digoxin Concentrations
Twenty-four hours after the thirteenth dose of digoxin, 0.25 mg, SDC in four patients was less than 0.4 ng/ml and the average value of 0.5 ng/ml was not statistically different from control. With the 0.5 mg/day dose, however, all SDC were greater than control values and the mean figure of 0.88 ng/ml was statistically greater than control. As with the STI In conclusion, the present study demonstrates that two weeks of therapy with 0.25 mg digoxin daily exerts a positive inotropic effect as reflected by shortening of STI. At a higher oral maintenance dose of 0.5 mg/day, greater shortening of STI occurred and shortening of QS2i significantly correlated with increase in SDC. Further refinement of SDC and STI measurements and study of larger numbers of patients would probably improve the correlation between mean SDC and STI values. However, it is likely that individual variations will still not permit an assessment of extent of positive inotropic effect solely on the basis of SDC levels.
